(3S)-N-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)-3-amino-3-phenylpropanamide | 1270014-28-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3S)-N-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)-3-amino-3-phenylpropanamide
• 英文别名: (3S)-3-amino-3-phenyl-N-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl]propanamide
• CAS: 1270014-28-2
• 化学式: C₂₀H₂₄N₆O
• 分子量: 364.45
• InChiKey: IKRGWFWQFAOMLN-LWKPJOBUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  99.9
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] HETEROARYL BTK INHIBITORS<br/>[FR] INHIBITEURS HÉTÉROARYLES DE BTK
  申请人：BIOGEN IDEC INC

  公开号：WO2011029043A1

  公开（公告）日：2011-03-10

  The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

  本发明提供了作为Btk抑制剂有用的化合物，其组成物以及使用这些化合物的方法。
• HETEROARYL BTK INHIBITORS
  申请人：Bui Minna

  公开号：US20120157442A1

  公开（公告）日：2012-06-21

  The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

  本发明提供了作为Btk抑制剂的有用化合物、其组合物以及使用它们的方法。
• Removable stent and method of production
  申请人：Mattson Erney

  公开号：US20120158122A1

  公开（公告）日：2012-06-21

  A removable porous stent is disclosed, which can be placed in tubular structures. In at least one embodiment, it can be placed at locations, which are unsuitable for permanent stents, like across important branches in the vasculature preferably in combination with anticoagulation. The walls of the stent are freely permeable for the blood flow. A temporary stent can be used during treatment of dissections with involvement of side branches. The dissected membrane is relocated to its original place and held in place by the stent until the healing process has reattached the membrane. At this point the stent will be removed. The removable stent can also be used, in at least one embodiment, as a carrier of chemotherapy and/or radiation to be placed in tubular structures for local treatment of cancer. The time for treatment is controlled and finished at removal. This approach will give the possibility to increase dosages and reduce side effects. In at least one embodiment, the stent is formed by at least one continuous thread arranged in interconnected loops and having a reversible bind-off at one end of the tubular body, mechanically securing each loop at said end of the tubular body apart from a single releasable loop. This loop is preferably extended beyond the tubular structure of the stent enabling an initiation of the removal at a distance from the treatment site.
• US8945207B2
  申请人：——

  公开号：US8945207B2

  公开（公告）日：2015-02-03
• US9029359B2
  申请人：——

  公开号：US9029359B2

  公开（公告）日：2015-05-12